- Grindeks Group has introduced CDMO and out-licensing services as part of a strategic shift under its new CEO.
- The company identified unused capacity across its manufacturing sites and will now offer development, analytical and GMP manufacturing support for APIs and finished dosage forms.
Grindeks Group has announced the introduction of CDMO and out-licensing services, marking a shift in its business development strategy under its new leadership. The company stated that although it has focused on its own brand portfolio over the past decade, a review of its manufacturing sites revealed available capacity that could support external partnerships.
The assessment covered facilities in Latvia, Estonia and Slovakia, identifying unused equipment and 24/7 production units with potential for broader utilisation. Grindeks noted that its experience working with external CDMOs has reinforced its understanding of the value these partners provide in flexibility, speed and navigating pharmaceutical development and manufacturing complexity.
The company will now offer development, analytical and manufacturing services across all stages of API and finished dosage form development. These services will support projects from early research through to full GMP production. Grindeks is positioning this expansion as a way to provide pharmaceutical collaborators with access to its capabilities and infrastructure.
Alongside the CDMO offering, Grindeks will also provide ready-to-file dossiers and marketing authorisation packages intended for EU and international markets. These packages are aimed at companies seeking to advance products through regulatory pathways with established documentation support.
